Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study
| Autor: | Zhi-Yu Zeng, Ying-Hui Li, Feng-Sui Chen, Qian Huang, Xiao-Ling Zhou, Zhi-Xian Wu, Li-Rong Cai, Shi-An Zhang, Dongliang Li, Hai-Cong Wu |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Reproductive Techniques Assisted Combination therapy medicine.disease_cause Antiviral Agents Gastroenterology law.invention 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Randomized controlled trial law Telbivudine Internal medicine Immune Tolerance medicine Humans Hepatitis B e Antigens Seroconversion Tenofovir Hepatitis B virus Hepatology business.industry Viral Load Hepatitis B medicine.disease HBeAg 030220 oncology & carcinogenesis DNA Viral Drug Therapy Combination Female 030211 gastroenterology & hepatology Preconception Care business Viral load medicine.drug |
| Zdroj: | European Journal of Gastroenterology & Hepatology. 31:832-835 |
| ISSN: | 0954-691X |
| DOI: | 10.1097/meg.0000000000001345 |
| Popis: | Background Immune-tolerant chronic hepatitis B (CHB) patients awaiting assisted reproduction (AR) are required to initiate antiviral therapy because of laboratory safety concerns. The antiviral therapy in this group has not been well assessed. We sought to explore the efficacy and safety of the combination therapy (COM) of tenofovir (TDF) and telbivudine (LdT). Patients and methods In this open-label, randomized, controlled study, we enrolled and randomized hepatitis B virus e-antigen (HBeAg)-positive CHB patients awaiting AR into the study COM group and the control (TDF) group. The COM group received combination therapy of TDF and LdT, and the TDF group received a single treatment of TDF. The patients were followed up for at least 48 weeks. The primary endpoint was the proportion of patients with undetectable HBV DNA level at week 12. Results A total of 121 patients were recruited into the COM group (n=60) and the TDF group (n=61). The percentages of patients with undetectable HBV DNA levels were 90.0% (54/60) in the COM group and 67.2% (41/61) (P=0.002) in the TDF group at week 12; the percentages were 96.6% (58/60) in the COM group and 85.2% (52/61) in the TDF group at week 48 (P=0.028), respectively. HBeAg seroconversion occurred in 5/60 (8.3%) patients in the COM group and 2/61 (3.3%) patients in the TDF group at week 48 (P=0.233). Conclusion TDF and LdT combination therapy shows a rapid antivirological response in immune-tolerant CHB patients awaiting AR, which provide an alternative for this group at AR centers. However, the HBeAg seroconversion rate is unsatisfactory in the short term. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|